No, oral testosterone should not be prescribed for female patients as an alternative to transdermal testosterone
The most recent and authoritative guideline explicitly recommends against using testosterone preparations formulated for men (including oral formulations) in women due to lack of safety and efficacy data specific to female populations 1.
Key Guideline Recommendations for Women
The 2014 Endocrine Society Clinical Practice Guideline on androgen therapy in women provides clear direction 1:
Recommendation 5.1: Suggests against the treatment of women with testosterone preparations formulated for men or those formulated by pharmacies due to lack of data concerning efficacy and safety (Grade 2|QEEE)
Recommendation 5.2: If testosterone therapy is to be given, use an approved non-oral preparation for women (such as transdermal patch, gel, or cream) if available (Grade 2|QEEE)
The 2019 Global Consensus Position Statement reinforces this, stating that use of any testosterone preparation resulting in supraphysiologic concentrations, including formulations designed for men, is not recommended 2.
Why Oral Testosterone Is Inappropriate for Women
Dosing and Safety Concerns
Oral testosterone formulations approved for men deliver doses far exceeding physiologic female ranges. The FDA-approved testosterone products are specifically indicated for "replacement therapy in males" with primary or hypogonadotropic hypogonadism 3. These formulations:
- Are dosed to achieve male physiologic levels (300-1000 ng/dL)
- Would produce supraphysiologic testosterone concentrations in women
- Lack any safety or efficacy data in female populations
Historical Context
Older oral testosterone preparations (not testosterone undecanoate) have been associated with potential liver toxicity 4. While oral testosterone undecanoate has been used in Europe for men, it was noted as "not approved for clinical use in the United States" in the male hypogonadism guidelines 5, 6 and has never been studied or approved for women.
What Should Be Done Instead
Insurance Appeal Process
The appropriate first step is to work with the patient to appeal the insurance denial for the FDA-approved transdermal testosterone patch, which is the only evidence-based formulation for women with hypoactive sexual desire disorder (HSDD) 2.
Off-Label Alternatives (If Appeal Fails)
If an approved female testosterone preparation remains unavailable after appeal, the 2019 Global Consensus provides guidance 2:
- Off-label prescribing of an approved male transdermal formulation (gel or patch) may be reasonable
- Critical requirement: Hormone concentrations must be maintained in the physiologic female range (typically 15-70 ng/dL total testosterone for premenopausal women)
- This requires careful dose titration—typically using fractions of male doses
- Baseline testosterone level should be measured before starting
- Monitor testosterone levels at 3-6 weeks after initiation, then every 6 months 2
Monitoring Requirements
When using any testosterone preparation in women 1, 2:
- Measure baseline total testosterone
- Reassess at 3-6 weeks to ensure levels remain in physiologic female range
- Monitor every 6 months for signs of androgen excess (acne, hirsutism, voice changes)
- Discontinue if no benefit by 6 months 2
Critical Safety Considerations
Compounded "bioidentical" testosterone cannot be recommended due to lack of evidence for efficacy and safety, unless no authorized equivalent preparation is available 2. Even then, the compounding pharmacy must be compliant with Good Manufacturing Practice standards.
Testosterone therapy in women is only evidence-based for postmenopausal women with HSDD after formal biopsychosocial assessment 2. The guidelines recommend against generalized use for other indications including infertility, cognitive dysfunction, cardiovascular health, bone health, or general well-being 1.
Bottom Line
Prescribing oral testosterone formulated for men to a female patient is not appropriate medical practice. The correct approach is to appeal the insurance denial for the transdermal patch, or if that fails, use a male transdermal formulation at carefully titrated doses that maintain female physiologic testosterone levels—never an oral formulation designed for male replacement therapy.